Floatz logo

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)

Lymphoma

Children's Cancer and Leukaemia Groupprotein_peptidePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
65/ 100

Competitive context

243 Active assets in the Lymphoma cohort.

Asset / SponsorPhaseRating
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
The Lymphoma Academic Research Organisation
Phase 4BBB
VINBLASTINE
Intensity Therapeutics, Inc.
Phase 4BBB
BLEOMYCIN
Shandong Provincial Hospital
Phase 4BB
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
City of Hope Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) is also rated in:

Adult Acute Lymphocytic LeukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
L1 Childhood Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid MalignanciesDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →